United Therapeutics Stock Today
| UTHR Stock | USD 313.60 5.25 1.65% |
PerformanceVery Weak
| Odds Of DistressLow
|
United Therapeutics is selling at 313.60 as of the 20th of March 2025; that is 1.65% down since the beginning of the trading day. The stock's lowest day price was 307.64. United Therapeutics has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of June 1999 | Category Healthcare | Classification Health Care |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. The company has 44.91 M outstanding shares of which 2.07 M shares are at this time shorted by private and institutional investors with about 4.69 trading days to cover. More on United Therapeutics
Moving together with United Stock
Moving against United Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
United Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President COO | Michael Benkowitz | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Excise Tax Activities | Animal Testing | ||||
| Average Analyst Recommendation | |||||
Debt LevelsUnited Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand United Therapeutics' financial leverage. It provides some insight into what part of United Therapeutics' total assets is financed by creditors.
| |||||
United Therapeutics (UTHR) is traded on NASDAQ Exchange in USA. It is located in 1000 Spring Street, Silver Spring, MD, United States, 20910 and employs 1,305 people. United Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 14.08 B. United Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 44.91 M outstanding shares of which 2.07 M shares are at this time shorted by private and institutional investors with about 4.69 trading days to cover.
United Therapeutics currently holds about 2.26 B in cash with 1.33 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 49.55.
Check United Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of United Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in United Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in United Therapeutics. Please pay attention to any change in the institutional holdings of United Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check United Ownership Details
United Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Alliancebernstein L.p. | 2024-12-31 | 709 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 620.6 K | |
| Pacer Advisors, Inc. | 2024-12-31 | 597.6 K | |
| Arrowstreet Capital Limited Partnership | 2024-12-31 | 542.4 K | |
| Fuller & Thaler Asset Management Inc | 2024-12-31 | 532.9 K | |
| Northern Trust Corp | 2024-12-31 | 488.9 K | |
| Hhg Plc | 2024-12-31 | 469 K | |
| Norges Bank | 2024-12-31 | 430.1 K | |
| Genworth Financial Wealth Mgmt Inc | 2024-12-31 | 429.2 K | |
| Wealthfront Advisers Llc | 2024-12-31 | 18.3 M | |
| Blackrock Inc | 2024-12-31 | 5.4 M |
United Therapeutics Historical Income Statement
United Stock Against Markets
United Therapeutics Corporate Management
| Holly Hobson | Associate Resources | Profile | |
| JD MBA | Chairman Founder | Profile | |
| Gil Golden | Senior Officer | Profile | |
| Dewey CFA | Head Relations | Profile | |
| Kevin Gray | Senior Logistics | Profile |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.